PolyPeptide Group: Overview, Contacts & Employment

About PolyPeptide Group

Industry

Pharmaceutical Manufacturing

Website

polypeptide.com

Headquarters

Neuhofstrasse 24, Baar, CH

Company size

1001-5000

Founded

1996

PolyPeptide Group AG, together with its consolidated subsidiaries, is a focused Contract Development & Manufacturing Organization (CDMO) specializing in the development and manufacturing of synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products, as well as generic peptides and peptides used in cosmetics. Headquartered at Neuhofstrasse 24 in Baar, Switzerland, the company primarily serves pharmaceutical and biotech clients, supporting them from pre-clinical through commercial stages and contributing to the health of millions of patients worldwide. Its active custom project pipeline reflects ongoing opportunities in novel drug therapies addressing both widespread and rare diseases. Originally established in 1952 and operating under its current structure since 1996, PolyPeptide now employs more than 1,400 people across a global network of six GMP-certified facilities in Europe, the U.S., and India. The company operates within the pharmaceutical manufacturing industry, and its shares (SIX: PPGN) are listed on the SIX Swiss Exchange.